Sangamo Therapeutics Soars 37.14% on Eli Lilly Deal

Sangamo Therapeutics' stock surged 37.14% in pre-market trading on April 4, 2025, driven by a significant licensing agreement with Eli Lilly and Company.

Sangamo Therapeutics has entered into a licensing agreement with Eli Lilly and Company, granting Lilly the rights to use Sangamo's proprietary capsid, STAC-BBB, for up to five potential disease targets. This capsid has shown strong blood-brain barrier penetration and neuronal transduction in nonhuman primates, making it a valuable tool for delivering genomic medicines to the central nervous system.

Under the terms of the agreement, Sangamo will receive an $18 million upfront license fee and is eligible for up to $1.4 billion in additional licensed target fees and milestone payments, along with tiered royalties on potential net sales. This deal marks the third agreement with a pharmaceutical company since the discovery of STAC-BBB in March 2024, highlighting the growing industry interest in Sangamo's capsid delivery technology.

Sangamo Therapeutics is dedicated to developing genomic medicines for serious neurological diseases, leveraging its zinc finger epigenetic regulators and capsid discovery platform. The company's pipeline includes multiple partnered programs and opportunities for further collaboration and investment.